John M. Kirkwood

Researchers Laurence Booth, Jane L. Roberts, and others discuss GZ17-6.02's efficacy in killing uveal melanoma cells. They cover the compound's components, safety evaluations, phase I trials, interactions with inhibitors, and its impact on cell signals for tumor cell elimination.